Adult Vaccines Market Report by Disease wise (Influenza, Cervical Cancer, Zoster, MMR, Pneumococcal, Meningococcal, Hepatitis, Tdap, Travel and Miscellaneous, Varicella) and Countries and Companies Analysis 2026-2034

Global Adult Vaccines Market Size and Forecast 2026-2034

The global adult vaccines market will grow from US$ 23.11 Billion in 2025 to US$ 39.44 Billion in 2034, at a Compound Annual Growth Rate (CAGR) of 6.12% from 2026 to 2034. Market growth is driven by rising awareness of preventive healthcare, increasing government immunization programs, and the growing prevalence of infectious diseases among adults. Technological advancements in vaccine development, expanding healthcare infrastructure, and strong demand for influenza, pneumococcal, and COVID-19 vaccines are expected to further accelerate industry expansion during the forecast period.

Global Adult Vaccines Market Outlooks

Adult vaccines are biological preparations designed to protect adults from infectious diseases by strengthening the body's immune system. These vaccines help prevent illnesses such as influenza, hepatitis, shingles, pneumococcal disease, tetanus, HPV, and COVID-19. Adult vaccination is especially important for older people, healthcare workers, pregnant women, travelers, and individuals with chronic diseases or weakened immunity. Vaccines reduce the risk of severe infections, hospitalization, long-term complications, and death, while also lowering healthcare costs and improving public health outcomes.

The popularity of adult vaccines has increased worldwide due to growing awareness about preventive healthcare, rising aging populations, and frequent outbreaks of infectious diseases. Governments, healthcare organizations, and pharmaceutical companies are actively promoting adult immunization programs through public campaigns and vaccination drives. The COVID-19 pandemic further accelerated vaccine acceptance and highlighted the importance of immunization in disease prevention. Developed regions such as North America and Europe lead in vaccination coverage, while emerging economies in Asia-Pacific and Latin America are witnessing rapid growth due to improving healthcare infrastructure and increasing healthcare spending.

Adult Vaccines Companies Pipeline Worldwide

Rank Company Vaccine Pipeline Focus Area Development Stage

1 Moderna mRNA-1647 Cytomegalovirus (CMV) prevention and maternal immunization Phase III

2 Moderna mRNA-1083 Combination Influenza + COVID-19 vaccine for adults Phase III / Regulatory Review

3 Pfizer ABRYSVO RSV prevention in high-risk adults Approved / Expanded Indication

4 GSK Arexvy RSV prevention for adults and elderly populations Regulatory Expansion

5 Moderna mRNA-1010 Seasonal influenza prevention Phase III

6 Sanofi RSV + hMPV Combination Vaccine Broad respiratory virus protection Phase I/II

7 Pfizer and Valneva VLA15 Lyme disease prevention Phase III

8 Moderna mRNA-1403 Norovirus prevention Phase III

9 CureVac and GSK H5N1 mRNA Vaccine Pandemic preparedness and avian influenza protection Phase I

10 Moderna mRNA-1189 / mRNA-1195 Epstein-Barr Virus (EBV) prevention Early Clinical Stage

Top Adult Vaccines launches worldwide

Rank Company Adult Vaccine Launch Focus Area Launch / Approval Date

1 Pfizer ABRYSVO Expanded Adult Indication RSV prevention in adults aged 18-59 at high risk 22-Oct-24

2 Pfizer ABRYSVO EU Expanded Approval RSV-related lower respiratory tract disease prevention 1-Apr-25

3 GSK AREXVY Expanded U.S. Approval RSV vaccine for adults aged 50-59 at increased risk 7-Jun-24

4 GSK AREXVY Expanded EU Approval RSV prevention in high-risk adults aged 50-59 29-Aug-24

5 Moderna mRNA-1083 Combination Vaccine Combined COVID-19 and influenza protection June 10, 2024 clinical launch update

6 Moderna mRESVIA RSV Vaccine RSV prevention in older adults May-24

7 Sanofi Novavax-Sanofi COVID Vaccine Commercialization COVID-19 and influenza combination vaccine development 10-May-24

8 GSK AREXVY Long-Term Protection Program Multi-season RSV protection for adults 8-Oct-24

9 Pfizer ACIP Expanded Recommendation for ABRYSVO RSV vaccination recommendation expansion 16-Apr-25

10 GSK AREXVY Expanded Review Filing RSV vaccine for adults aged 18-49 at risk 14-Jul-25

Growth Drivers of the Adult Vaccines Market

Rising Awareness About Preventive Healthcare

Growing awareness regarding preventive healthcare is one of the major drivers of the adult vaccines market worldwide. Governments, healthcare organizations, and pharmaceutical companies are increasingly educating people about the importance of immunization in preventing infectious diseases. Adults are becoming more conscious of maintaining long-term health and reducing the risk of severe illnesses such as influenza, pneumonia, hepatitis, and shingles. Public health campaigns, social media awareness programs, and employer-sponsored wellness initiatives are encouraging adults to receive routine vaccinations. The COVID-19 pandemic also significantly changed public perception toward vaccines, highlighting their role in reducing hospitalization and mortality rates. Healthcare professionals now recommend vaccination as an essential part of adult healthcare management, especially for older adults and people with chronic conditions. Increased awareness has improved vaccine acceptance rates across both developed and developing countries. As consumers continue prioritizing preventive care over expensive medical treatments, the demand for adult vaccines is expected to witness sustained growth during the forecast period. March 2024, Dr. Reddy's Laboratories forged an exclusive distribution agreement with Sanofi Healthcare India Private Limited. This partnership is aimed at promoting and distributing sanofi's vaccine offerings throughout India. The deal was designed to improve access to vaccines and, at the same time, bolster Dr. Reddy's position in the adult and pediatric vaccine sectors

Increasing Aging Population Worldwide

By 2030, 1 in 6 people in the world will be aged 60 years or over. At this time the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world's population of people aged 60 years and older will double (2.1 billion). The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million.The rapidly growing aging population across the world is another key growth driver for the adult vaccines market. Older adults are more vulnerable to infectious diseases because of weakened immune systems and age-related health conditions such as diabetes, cardiovascular diseases, and respiratory disorders. Vaccines play a crucial role in protecting elderly individuals from severe complications and hospitalizations caused by diseases like influenza, pneumococcal infections, shingles, and COVID-19. According to global demographic trends, the proportion of people aged 60 years and above is increasing steadily, particularly in countries such as Japan, Germany, China, and the United States. Governments and healthcare providers are focusing on improving elderly healthcare services, including adult immunization programs. In addition, rising life expectancy and better healthcare access are encouraging seniors to adopt preventive healthcare measures. Pharmaceutical companies are also developing advanced vaccines specifically designed for older adults with enhanced efficacy. This expanding elderly population is expected to create strong long-term demand for adult vaccination products globally.

Technological Advancements in Vaccine Development

Continuous technological advancements in vaccine development are significantly contributing to the expansion of the adult vaccines market. Innovations such as mRNA technology, recombinant vaccines, conjugate vaccines, and improved adjuvant systems have enhanced vaccine effectiveness, safety, and production speed. The success of mRNA-based COVID-19 vaccines demonstrated the potential of advanced vaccine platforms in responding quickly to infectious disease outbreaks. Pharmaceutical companies are heavily investing in research and development activities to introduce next-generation vaccines targeting multiple diseases with improved immune responses and fewer side effects. Technological progress has also improved manufacturing efficiency, storage capabilities, and global vaccine distribution systems. In addition, the use of artificial intelligence, genomics, and biotechnology is accelerating vaccine discovery and clinical development processes. Combination vaccines that protect against multiple infections in a single dose are becoming increasingly popular among adults due to convenience and better compliance. These advancements are expected to support market growth by expanding product availability and improving vaccination coverage worldwide. December 2025, Sanofi announced the acquisition of Dynavax Technologies. This acquisition has enabled the company to own a marketed adult hepatitis B vaccine and a shingles vaccine candidate. This move has strengthened the position of the company in the market for adult vaccines.

Challenges of the Adult Vaccines Market

Vaccine Hesitancy and Misinformation

Vaccine hesitancy remains one of the biggest challenges affecting the growth of the adult vaccines market. Many individuals are reluctant to receive vaccines because of misinformation, safety concerns, religious beliefs, or lack of trust in healthcare systems. The rapid spread of false information through social media platforms has increased public confusion regarding vaccine side effects and effectiveness. In several countries, anti-vaccination movements have negatively influenced public perception toward immunization programs. Adults often underestimate their risk of infectious diseases and may believe vaccines are only necessary for children. This limited awareness reduces vaccination rates, especially in developing and low-income regions. In addition, fear of adverse reactions and concerns about newly developed vaccines can delay acceptance among the population. Governments and healthcare organizations face difficulties in combating misinformation and educating the public effectively. Unless proper awareness campaigns, transparent communication, and healthcare education initiatives are strengthened, vaccine hesitancy may continue to limit the overall growth potential of the global adult vaccines market.

High Costs and Limited Accessibility in Developing Regions

High vaccine costs and limited access to healthcare are major barriers to the growth of the adult vaccines market, particularly in developing and underdeveloped countries. Advanced vaccines often require significant investment in research, production, transportation, and cold-chain storage systems, making them expensive for many healthcare providers and patients. In low-income regions, inadequate healthcare infrastructure and limited reimbursement policies further reduce vaccine affordability and availability. Rural populations frequently lack access to hospitals, pharmacies, and immunization centers, resulting in lower vaccination coverage. In some countries, adult vaccination programs are not prioritized relative to pediatric immunization initiatives, resulting in insufficient government funding and awareness. Additionally, supply chain disruptions and shortages of trained healthcare professionals can delay vaccine distribution in remote areas. Economic inequalities and limited insurance coverage also discourage adults from receiving recommended vaccines. Addressing these challenges will require stronger government support, international healthcare partnerships, and investment in affordable vaccination programs to improve global immunization access.

TdaP Adult Vaccines Market

The TdaP adult vaccines market is experiencing significant growth due to increasing awareness regarding booster immunization and protection against tetanus, diphtheria, and pertussis. These vaccines are widely recommended for healthcare workers, caregivers, pregnant women, and adults who require regular booster doses to maintain immunity. Rising incidences of pertussis outbreaks across several countries have strengthened the importance of adult vaccination programs. Healthcare authorities in many nations advise adults to receive a TdaP booster every ten years, creating continuous market demand. In addition, maternal immunization guidelines recommending TdaP vaccination during every pregnancy to protect newborns from whooping cough have substantially increased vaccine adoption. Governments and healthcare organizations are also integrating TdaP vaccines into workplace and occupational health programs, particularly in hospitals and public service sectors. Increasing public health awareness, improved vaccination accessibility, and strong government support are expected to continue driving the expansion of the global TdaP adult vaccines market during the forecast period.

Meningococcal Adult Vaccines Market

The meningococcal adult vaccines market is gaining strong momentum worldwide due to the increasing prevalence of meningitis outbreaks and rising awareness about disease prevention among high-risk populations. Adults such as travelers, military personnel, healthcare workers, and university students living in shared accommodations are highly vulnerable to meningococcal infections. As a result, governments and healthcare institutions are actively promoting vaccination against meningococcal serogroups including A, C, W, Y, and B. In several countries, especially across North America and Europe, colleges and universities have made meningococcal vaccination mandatory for students residing in dormitories. Growing international travel to endemic regions has further contributed to the demand for adult meningococcal vaccines. In addition, enhanced disease surveillance systems and rapid outbreak response initiatives are supporting market growth. Pharmaceutical companies are also focusing on developing advanced vaccines with broader serogroup coverage and improved effectiveness, which is expected to strengthen market expansion in the coming years.

Hepatitis Adult Vaccines Market

The hepatitis adult vaccines market continues to grow steadily as hepatitis A and B remain major global public health concerns due to their chronic and potentially life-threatening complications. Adult vaccination programs are increasingly emphasizing hepatitis prevention, particularly among healthcare professionals, patients with liver disorders, travelers visiting high-risk regions, and individuals exposed to unsafe medical or lifestyle practices. Governments and international healthcare organizations are actively promoting hepatitis immunization through national vaccination schedules and disease elimination initiatives. Organizations such as the World Health Organization are supporting widespread vaccination campaigns to reduce the global burden of hepatitis infections. Increasing awareness regarding liver health and preventive healthcare has also encouraged higher vaccine adoption among adults. Furthermore, the development of combination vaccines and long-lasting vaccine formulations has improved patient convenience and compliance rates. Expanding healthcare infrastructure, improved vaccine accessibility, and rising investments in immunization programs are expected to continue driving growth in the global adult hepatitis vaccines market over the forecast period.

United States Adult Vaccines Market

The United States adult vaccines market is highly advanced and continues to demonstrate strong growth due to its well-established healthcare infrastructure, supportive regulatory framework, and high public awareness regarding preventive healthcare. Government organizations such as the Centers for Disease Control and Prevention (CDC), along with Medicare and private insurance providers, ensure broad access to adult vaccines including influenza, shingles, pneumococcal, and TdaP vaccines. The COVID-19 pandemic significantly strengthened the country's immunization infrastructure and accelerated vaccine adoption among adults. Public health campaigns, digital vaccine tracking systems, and high healthcare literacy levels have further contributed to strong vaccination rates across the nation. The United States also maintains a leading position in vaccine research, development, and innovation, supported by major pharmaceutical companies operating within the country. Continuous product approvals are strengthening market expansion. In October 2024, Pfizer received FDA approval for ABRYSVO(R), a bivalent RSV vaccine designed to prevent lower respiratory tract disease in high-risk adults aged 18 to 59 years.

Germany Adult Vaccines Market

Germany represents one of the leading adult vaccines markets in Europe due to its universal healthcare coverage, strong government involvement, and well-structured immunization policies. The country actively promotes adult vaccination through updated recommendations issued by the Robert Koch Institute, encouraging regular immunization among adults and elderly populations. High uptake of influenza vaccines, routine TdaP booster doses, and increasing awareness regarding shingles and pneumococcal vaccines are contributing significantly to market growth. Germany also benefits from strong public confidence in vaccine safety and effectiveness, helping reduce vaccine hesitancy among citizens. The country's collaboration with European healthcare agencies and pharmaceutical companies supports innovation, efficient vaccine supply chains, and improved healthcare access. Increasing focus on preventive healthcare and aging population trends are also strengthening market demand. In April 2025, Pfizer received approval from the European Commission for its Abrysvo vaccine to prevent RSV-related lower respiratory tract illness among adults aged 18 to 59 years who are at elevated risk across all European Union member countries.

India Adult Vaccines Market

India's adult vaccines market is witnessing steady expansion due to rising health awareness, increasing prevalence of chronic diseases, and growing government support for immunization programs. Although vaccination efforts in India have traditionally focused on children, adult immunization is gaining greater importance, especially for diseases such as hepatitis B and influenza. Healthcare professionals, elderly populations, and high-risk adults are increasingly being encouraged to receive preventive vaccines. Rapid urbanization, expanding healthcare infrastructure, medical tourism growth, and rising private healthcare investments are also driving demand for adult vaccines across the country. However, disparities in healthcare access between urban and rural areas continue to present challenges for widespread vaccine coverage. Public-private partnerships, educational campaigns, and awareness programs are playing an important role in improving vaccine literacy among adults. India's strong pharmaceutical manufacturing sector further supports vaccine affordability and supply. In August 2024, Artemis Hospitals collaborated with Pfizer India to launch a Centre for Adult Vaccination aimed at strengthening preventive healthcare services and reducing vaccine-preventable diseases among adults.

Saudi Arabia Adult Vaccines Market

Saudi Arabia's adult vaccines market is growing rapidly due to strong government healthcare initiatives, increasing awareness of preventive healthcare, and mandatory vaccination requirements for Hajj and Umrah pilgrims. The Ministry of Health actively promotes adult immunization programs focusing on influenza, meningococcal, and hepatitis vaccines to control infectious disease risks associated with large religious gatherings and international travel. Seasonal pilgrimages create unique public health challenges, making vaccination an essential strategy for disease prevention and outbreak control. In addition, the country's Vision 2030 healthcare reforms emphasize preventive medicine and improved healthcare services, further supporting market growth. Rising cases of chronic diseases such as diabetes and cardiovascular disorders among adults have also increased demand for vaccines that help reduce infection-related complications. Expanding public healthcare investments and improved healthcare infrastructure are strengthening vaccine accessibility across the country. In September 2023, the Saudi Arabian government invested approximately $133 million to establish a vaccine and medicine manufacturing facility aimed at reducing dependence on imported pharmaceutical products and improving emergency healthcare preparedness.

Adult Vaccine Market Segments

Disease wise - Adult Vaccines Market

• Influenza
• Cervical Cancer (HPV)
• Zoster (Shingles)
• MMR (Measles, Mumps, and Rubella Vaccine)
• Pneumococcal
• Meningococcal
• Hepatitis
• TdaP
• Travel and Miscellaneous
• Varicella

Disease wise - Numbers of Vaccinated Adults

• Influenza
• Cervical Cancer (HPV)
• Zoster (Shingles)
• MMR
• Pneumococcal
• Meningococcal
• Hepatitis
• TdaP
• Varicella

Countries

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Malaysia
• Indonesia
• New Zealand

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• South Africa
• Saudi Arabia
• United Arab Emirates

All companies have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• GlaxoSmithKline, plc.
• AstraZeneca plc
• Sanofi Pasteur
• Pfizer, Inc.
• CSL Limited